Wed, Dec 12|
Joey's Bar & Grill
The Only CDK4 & CDK6 Inhibitor Approved Across HR+, HER2 - MBC
Verzenio is indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2- negative (HER2-) advanced or metastatic breast cancer (MBC)
Time & Location
Dec 12, 2018, 5:30 PM
Joey's Bar & Grill, 344 Chandler St, Worcester, MA 01602, USA
About The Event
Blanca Ledezema, APN, APNP, MN, MS, NP
UCLA Hematology Oncology Santa Monica, CA
This program will present efficacy and safety data for Verzenio, a CDK4 + CDK6 inhibitor approved in comibination with fluvestrant, in combination with an Al, and as a single age for HR+, HER2- advanced or MMBC. Information about mechanism of action and dosing will also be presented.
~Discuss the unmet needs for women with HR+, HER2- MBC
~Examine the efficacy and safety profile of Verzenio
~Review practical considerations for the use of Verzenio
RSVP to Aimee Ferry at Ferry_aimee_R@lilly.com or by phone at 603-475-4602.